ERBB2 and breast cancer: In the CLEOPATRA study, which established the combination of docetaxel with dual anti-HER2 blockade (trastuzumab and pertuzumab) as the standard first-line treatment for advanced HER2+ BC, higher TILs were associated with better OS [42].